Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals Inc has secured $63.5 million in Series B financing.

• Source: biospace
• 410
• March 16, 2018